A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
NCT05830045
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
180
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors
Interventions
DRUG:
QLP2117
Sponsor
Qilu Pharmaceutical Co., Ltd.